364 results about "Human cell" patented technology

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.

The invention provides a grass carp sourced U6 promoter. The sequence of the grass carp sourced U6 promoter is shown as one of SEQ ID NO: 1-3. Three grass carp-derived U6 promoters are cloned, the transcriptional activity and cross-species adaptability of the three promoters are analyzed, results show that the three promoters can show transcriptional activity in fish cells and human cells, the transcriptional activity of ciU6-1 is remarkably higher than that of the other two promoters, heterologous DNA can be transcribed in various cells, and the expression of the ciU6-1 in the fish cells and the human cells is improved. And the method can be used for gene editing means based on Cas9.

The present disclosure provides compositions and methods for the targeted modification of RNA molecules by RNA prime editing. The compositions and methods may be conducted invitro or in vivo within cells (e.g., human cells) for the therapeutic correction of disease-causing mutations and / or installation of motifs or mutations in RNA molecules of interest as a tool for scientific research. The disclosure provides compositions and methods for conducting RNA prime editing of a target RNA molecule (e.g., an RNA transcript) that enables the incorporation of one or more nucleotide changes and / or targeted mutagenesis of a target RNA molecule. The nucleotide change can include a single-nucleotide change, an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides a variety of configurations of the RNA prime editors each comprising a nucleic acid programmable RNA binding proteins (napRNAbp), such as Cas13, and an RNA-dependent RNA polymerase (RDRP), which are provided as fusion proteins or which can be separately provided in trans. The RNA prime editors are guided to a target RNA site by a guide RNA, which can be a rpegRNA that includes a template region for the synthesis of an RNA sequence to be installed on the RNA molecule attached to an available 3′ terminus. In others embodiments, the RNA template can be provided in trans.

Disclosed are compositions comprising a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence or portion thereof of a target ribonucleic acid (RNA) sequence. The nucleic acid molecule may further encode one or more stabilization domains. The one or more stabilization domains may be configured to reduce a cellular nuclease activity compared to a nucleic acid molecule that does not comprise the one or more stabilization domains.

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

The present application relates to the technical field of small molecule drugs, in particular to a isoquinoline drug and its application in improving or treating digestive tract tumors, and aims to provide a compound, a pharmaceutical composition containing the compound and its application in treating colorectal cancer and gastric cancer, and provides a 3,13-position substituted berberine derivative, the drug itself has less toxicity and does not affect the growth of normal human cells, and has a good application prospect in the development of novel antitumor drugs, especially in the development of anti-digestive tract tumor drugs.

The present invention relates to a hybrid exosome formed by the fusion of a human cell-derived exosome and an artificial exosome. When an active ingredient labeled with a fluorescent material was attached or encapsulated in the hybrid exosome of the present invention and applied to cells, the active ingredient was observed in the cells. In addition, when the exosome was applied to skin tissue, fluorescence expression could also be observed in the dermal layer. Therefore, the hybrid exosome according to the present invention can be used as a novel drug delivery system.

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a human or humanized T cell receptor (TCR) from a human or humanized TCR locus comprising a non-human TCR non-coding sequence, and optionally a humanized T cell co-receptor (e.g., humanized CD4 and / or CD8 (e.g., CD8α and / or CD8β)), and / or a human or humanized major histocompatibility complex that binds the humanized T cell co-receptor (e.g., human or humanized MHC II (e.g., MHC II α and / or MHC II β chains) and / or MHC I (e.g., MHC Iα) respectively, and optionally human or humanized β2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. Methods for making the genetically engineered animals are also provided. Methods for using the genetically engineered animals for developing human therapeutics are also provided.

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

This disclosure provides compositions and methods for the activation and expansion of human T cells or NK cells using soluble monospecific antibody complexes.

The present disclosure provides T cell receptors (TCRs) that bind to antigenic peptides of MAGE-A10 presented by HLA-A molecules. Also provided are nucleic acids encoding such TCRs, vectors comprising such nucleic acids, cells comprising such TCRs, nucleic acids and vectors, and compositions comprising such TCRs, nucleic acids, vectors, and cells. Also provided are methods for treating diseases / conditions using, and medical uses of, such TCRs, nucleic acids, vectors, cells and compositions.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human transcription factor PU.1 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The antibody provided by the invention can specifically and sensitively recognize the human transcription factor PU.1 expressed in human cells / tissues, has good affinity to the PU.1 and excellent anti-interference capability, and has no cross reaction to other species of homologous proteins, so that the accuracy and reliability of immunodetection of the human PU.1 can be improved, the coincidence degree of a detection result and an actual situation is improved, and the human transcription factor PU.1 can be effectively identified. False positive or false negative results are effectively avoided, and an effective antibody tool and a detection means are provided for high-specificity, high-accuracy and high-sensitivity detection of the PU.1 protein.

Disclosed herein are compositions for engineering a human cell comprising a cell modulating agent or a vector encoding the cell modulating agent. Described herein are compositions comprising an engineered cell, wherein the engineered cell is an engineered human cell and comprises a modification such that the engineered cell is more resistant to an alkylating drug or a nucleoside analog relative to a non-engineered human cell. Various methods of treating a disease are provided, including, a method of treating cancer in a subject by administering the cell modulating agents and / or engineered cells as a therapeutic.

Provided are methods for treating colorectal cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.

The present invention relates to recellularization of xenogeneic tissue. Specifically, the present invention relates to recellularization of xenogeneic tissue, which enables transplantation of non-immunogenic biological tissue with improved durability and regenerative capacity by generating xenogeneic tissue having regenerative capacity through human cell recellularization after removal of galactose-alpha-1,3-galactose (α-Gal) xenoantigens and non-galactose (non-Gal) xenoantigens.

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

Systems and methods for highly-effective CRISPR-Cas based genomic editing within human chromosome 15q11-q13 have been developed as therapeutic interventions for Angelman Syndrome (AS). Selective single guide RNA molecules (sgRNAs) that impart enhanced CRISPR-Cas editing of genomic mutations associated with Angelman Syndrome in human cells are described. The engineered sgRNAs induce activity of non-pathogenic, paternal UBE3A alleles to reduce, reverse and / or prevent the causative neurodevelopmental defects of AS in a subject in need thereof. Compositions and methods of engineered crRNAs, sgRNAs thereof and ribonucleoprotein (RNP) complexes thereof are provided for enhanced genomic engineering with increased on-off target specificity and on-target editing efficacy for treatment of AS.

The present invention is a precursor crRNA for a type I CRISPR-Cas system having a modified nucleotide, in which at least one nucleotide is a modified nucleotide in a region comprising the 5'arm region of a first repeat sequence, the 5 '-side stem formation region of the first repeat sequence, and the ring formation region of the first repeat sequence.

Provided herein, inter alia, are compositions for treating Human T-cell lymphotropic virus type 1 (HTLV-1) associated diseases. The compositions include a protein having a zinc finger domain capable of binding a sequence within an HTLV-1 long terminal repeat (LTR). Further provided are methods of treating HTLV-1 associated diseases in a subject in need thereof. The methods include administering to the subject the protein including the zinc finger domain, or a nucleic acid encoding the protein.

The invention provides a method and a kit for detecting full-length mRNA of a human cell telomerase subunit TERT transcript, and belongs to the technical field of biology. The invention provides a method for detecting human cell telomerase subunit TERT transcript full-length mRNA, a specific reverse transcription primer TERT rt1 is adopted for reverse transcription to obtain cDNA, and if a sixth exon and a seventh exon of the telomerase subunit TERT can be detected in the cDNA, it is judged that a sample to be detected contains the human cell telomerase subunit TERT transcript full-length mRNA. The method disclosed by the invention can be used for distinguishing the full-length mRNA of TERT mRNA and other shear isomer mRNA, and a new technical means is provided for more conveniently, accurately and indirectly evaluating the activity of telomerase in cells.

A composition is provided comprising a cell population and pharmaceuticals derived from human gingival fibroblasts, present in proportions not found in natural gingival tissue, but having a cellular phenotype preferentially selected to express proteins favorable for angiogenesis and anti-inflammatory effects, while reducing the formation of cell populations that promote tumorigenesis and / or metalloproteinases that inhibit tissue regeneration. A method for producing such a composition that increases proliferation several times over compared to previously known methods is provided, and a method for using such a composition in a wide range of human cell therapies is also provided.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

An assay for autologous primary immune cells is described, in which individual blood cells can be functionally screened simultaneously for individual antigens of interest, such as T-cell epitopes, without the need for HLA haplotype-specific reagents. An oligonucleotide-labeled hash-tracking system, followed by deconvolution via single-cell sequencing, correlates antigen reactivity with individual T cells.

To provide a gene modified cell including a modified T cell receptor (TCR) alpha steady region gene in a genome of the gene modified cell.SOLUTION: There is provided a gene modified cell including in a genome thereof, a modified human T cell receptor (TCR) alpha steady region gene, the modified human TCR alpha steady region gene includes, from 5' to 3', a 5' region of the human TCR alpha steady region gene, an exogenous polynucleotide, and a 3' region of the human TCR alpha steady region gene. The modified human TCR alpha steady region gene is a gene modified human T cell or a gene modified cell derived from a human T cell, and in comparison with a non-modified control cell, expression of an endogenous TCR on a cell surface is suppressed.SELECTED DRAWING: Figure 1

We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8− / + subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.

The present invention discloses a 1,2,4-triazole-phenylacetamide α-glucosidase inhibitor and its preparation method and application. The chemical structure of this type of α-glucosidase inhibitor is shown in formula (I): #imgabs0# The 1,2,4-triazole-phenylacetamide α-glucosidase inhibitor disclosed by the present invention not only has good effects of inhibiting the activity of α-glucosidase and reducing postprandial blood sugar, but can be used as a lead compound for novel anti-diabetic research; it also has low toxicity to normal human cells and high safety; and the preparation method of the 1,2,4-triazole-phenylacetamide compound disclosed by the present invention is simple, the synthetic route is short, it is easy to prepare in large quantities, the price is low, and it is suitable for market promotion and application.

This document discloses compositions for use with engineered human cells, the compositions comprising a cell regulator or a carrier encoding a cell regulator. This document describes compositions comprising engineered cells, wherein the engineered cells are engineered human cells and contain modifications that make the engineered cells more resistant to alkylating drugs or nucleoside analogs compared to non-engineered human cells. Various methods for treating diseases are provided, including methods for treating cancer in a subject by administering cell regulators and / or engineered cells as therapeutic agents.